Skip to main content Skip to footer

Help the fight against COVID-19

Has a doctor or nurse said you are likely to have COVID-19 infection, or do you have any of these symptoms?
Continuous, new or worsening cough?
High temperature?
Loss or change to your sense of smell or taste?
And did you start to feel unwell in the last 6 days?
Are you aged 18 or over?

Then you could be eligible to join the AGILE trial which aims to find a treatment for people with COVID-19
If you would like to participate in the AGILE trial or find out more then contact your GP or the research team by one of the methods below.
Fill in this form

    Select centre (required)

    Or contact our sites
    Liverpool
    Tel: 0151 7064863
    Text: COVID to 07342 065915
    email: [email protected]
    Website: Clinical Research Facility, Liverpool
    Southampton
    Tel: 07469 565895
    email: [email protected]
    Web: Clinical Research Facility, Southampton
    Manchester
    Tel: 0161 906 7500
    email: [email protected]
    Web: Clinical Research Facility, Manchester

    Lancashire
    Tel: 01772 522031
    email: [email protected]
    Web: Clinical Research Facility, Lancashire
    London (King’s College Hospital)
    Tel: 07971367683
    email: [email protected]
    Web:  NIHR Wellcome Kings Clinical Research Facility

    More information about treatments being assessed in the AGILE platform study

    Molnupiravir. Patient recruitment in Liverpool, Manchester, Lancashire and London community hubs, where prospective patients whose symptoms began within the last 4 days will be contacted, informed about the trial and invited to participate in case they fall ill with COVID-19. You can find more information about Molnupiravir below, and if you have any further questions, please contact [email protected].

    Molnupiravir

    VIR-7831/7832. Patient recruitment in Liverpool and Southampton, where prospective patients whose symptoms began within the last 6 days will be contacted, informed about the trial and invited to participate if they have mild to moderate symptoms of COVID-19. You can find more information about VIR-7831/7832 below, and if you have further questions by contacting [email protected] (Liverpool) or [email protected] (Southampton).

    VIR-7831/7832

    Nitazoxanide. Recruitment of healthy volunteers for the first stage of this trial has completed in Liverpool. The second stage of this trial will be carried out in South Africa, recruiting patients with mild/moderate COVID-19 symptoms in Cape Town and Johannesburg. You can find more information about Nitazoxanide if you have further questions by contacting  [email protected]

    Nitazoxanide